International Journal of Cancer Management

Published by: Kowsar

Cancer-Testis Antigens: A Novel Group of Tumor Biomarkers in Ovarian Cancers

Zahra Taherian-Esfahani 1 , Atieh Abedin-Do 1 , Elahe Nikpayam 1 , Behnoosh Tasharofi 1 , Akram Ghahghaei Nezamabadi 2 and Soudeh Ghafouri-Fard 1 , *
Authors Information
1 Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Vali-e-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran
Article information
  • Iranian Journal of Cancer Prevention: December 2016, 9 (6); e4993
  • Published Online: December 6, 2016
  • Article Type: Review Article
  • Received: December 8, 2015
  • Revised: January 11, 2016
  • Accepted: December 3, 2016
  • DOI: 10.17795/ijcp-4993

To Cite: Taherian-Esfahani Z, Abedin-Do A, Nikpayam E, Tasharofi B, Ghahghaei Nezamabadi A, et al. Cancer-Testis Antigens: A Novel Group of Tumor Biomarkers in Ovarian Cancers, Int J Cancer Manag. 2016 ; 9(6):e4993. doi: 10.17795/ijcp-4993.

Copyright © 2016, Iranian Journal of Cancer Prevention. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. CTA-Based Immunotherapy in Ovarian Cancer
5. Conclusions
  • 1. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014; 384(9951): 1376-88[DOI][PubMed]
  • 2. Ranjbar R, Nejatollahi F, Nedaei Ahmadi AS, Hafezi H, Safaie A. Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) in Patients With Serous Ovarian Carcinoma and Their Clinical Significance. Iran J Cancer Prev. 2015; 8(4): 3428[DOI][PubMed]
  • 3. Nguyen L, Cardenas-Goicoechea SJ, Gordon P, Curtin C, Momeni M, Chuang L, et al. Biomarkers for early detection of ovarian cancer. Womens Health (Lond). 2013; 9(2): 171-85[DOI][PubMed]
  • 4. Prat J, Figo Committee on Gynecologic Oncology . FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. J Gynecol Oncol. 2015; 26(2): 87-9[DOI][PubMed]
  • 5. Maleki J, Nourbakhsh M, Shabani M, Korani M, Nourazarian SM, Ostadali Dahaghi MR, et al. 17beta-Estradiol Stimulates Generation of Reactive Species Oxygen and Nitric Oxide in Ovarian Adenocarcinoma Cells (OVCAR 3). Iran J Cancer Prev. 2015; 8(3): 2332[DOI][PubMed]
  • 6. Chester C, Dorigo O, Berek JS, Kohrt H. Immunotherapeutic approaches to ovarian cancer treatment. J Immunother Cancer. 2015; 3: 7[DOI][PubMed]
  • 7. Ghafouri-Fard S, Modarressi MH. Cancer-testis antigens: potential targets for cancer immunotherapy. Arch Iran Med. 2009; 12(4): 395-404[PubMed]
  • 8. Dianatpour M, Mehdipour P, Nayernia K, Mobasheri MB, Ghafouri-Fard S, Savad S, et al. Expression of Testis Specific Genes TSGA10, TEX101 and ODF3 in Breast Cancer. Iran Red Crescent Med J. 2012; 14(11): 722-6[DOI][PubMed]
  • 9. Ghafouri-Fard S. Expression of Cancer-Testis Antigens in Pediatric Cancers. Asian Pac J Cancer Prev. 2015; 16(13): 5149-52[PubMed]
  • 10. Ghafouri-Fard S, Modarressi MH. Expression of cancer-testis genes in brain tumors: implications for cancer immunotherapy. Immunotherapy. 2012; 4(1): 59-75[DOI][PubMed]
  • 11. Ghafouri-Fard S, Ousati Ashtiani Z, Sabah Golian B, Hasheminasab SM, Modarressi MH. Expression of two testis-specific genes, SPATA19 and LEMD1, in prostate cancer. Arch Med Res. 2010; 41(3): 195-200[DOI][PubMed]
  • 12. Ghafouri-Fard S, Shamsi R, Seifi-Alan M, Javaheri M, Tabarestani S. Cancer-testis genes as candidates for immunotherapy in breast cancer. Immunotherapy. 2014; 6(2): 165-79[DOI][PubMed]
  • 13. Ghafouri-Fard S, Seifi-Alan M, Shamsi R, Esfandiary A. Immunotherapy in Multiple Myeloma Using Cancer-Testis Antigens. Iran J Cancer Prev. 2015; 8(5): 3755[DOI][PubMed]
  • 14. Nelson PT, Zhang PJ, Spagnoli GC, Tomaszewski JE, Pasha TL, Frosina D, et al. Cancer/testis (CT) antigens are expressed in fetal ovary. Cancer Immun. 2007; 7: 1[PubMed]
  • 15. Wefers C, Lambert LJ, Torensma R, Hato SV. Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence. Gynecol Oncol. 2015; 137(2): 335-42[DOI][PubMed]
  • 16. Yoshihara K, Tsunoda T, Shigemizu D, Fujiwara H, Hatae M, Fujiwara H, et al. High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway. Clin Cancer Res. 2012; 18(5): 1374-85[DOI][PubMed]
  • 17. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991; 254(5038): 1643-7[PubMed]
  • 18. Poveda AM, Selle F, Hilpert F, Reuss A, Savarese A, Vergote I, et al. Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial. J Clin Oncol. 2015; 33(32): 3836-8[DOI][PubMed]
  • 19. Berek JS, Edwards RP, Parker LP, DeMars LR, Herzog TJ, Lentz SS, et al. Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study. Int J Gynecol Cancer. 2014; 24(9): 1583-9[DOI][PubMed]
  • 20. De Felice F, Marchetti C, Palaia I, Musio D, Muzii L, Tombolini V. Immunotherapy of ovarian cancer: The role of checkpoint inhibitors. J Immunol Res.
  • 21. Turnis ME, Korman AJ, Drake CG, Vignali DA. Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more. Oncoimmunology. 2012; 1(7): 1172-4[DOI][PubMed]
  • 22. Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A. 2010; 107(17): 7875-80[DOI][PubMed]
  • 23. Schmid BC, Oehler MK. New perspectives in ovarian cancer treatment. Maturitas. 2014; 77(2): 128-36[DOI][PubMed]
  • 24. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood. 2000; 96(9): 3102-8[PubMed]
  • 25. Peethambaram PP, Melisko ME, Rinn KJ, Alberts SR, Provost NM, Jones LA. A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu. Clinical Cancer Res. 2009; 15(18): 5937-44
  • 26. Zsiros E, Tanyi J, Balint K, Kandalaft LE. Immunotherapy for ovarian cancer: recent advances and perspectives. Curr Opin Oncol. 2014; 26(5): 492-500[DOI][PubMed]
  • 27. Kang J, Lee HJ, Jun SY, Park ES, Maeng LS. Cancer-Testis Antigen Expression in Serous Endometrial Cancer with Loss of X Chromosome Inactivation. PLoS One. 2015; 10(9): 137476[DOI][PubMed]
  • 28. Mirandola L, J. Cannon M , Cobos E, Bernardini G, Jenkins MR, Kast WM, et al. Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer. Int Rev Immunol. 2011; 30(2-3): 127-37[DOI][PubMed]
  • 29. Sharma S, Qian F, Keitz B, Driscoll D, Scanlan MJ, Skipper J, et al. A-kinase anchoring protein 3 messenger RNA expression correlates with poor prognosis in epithelial ovarian cancer. Gynecol Oncol. 2005; 99(1): 183-8[DOI][PubMed]
  • 30. Hasegawa K, Ono T, Matsushita H, Shimono M, Noguchi Y, Mizutani Y, et al. A-kinase anchoring protein 3 messenger RNA expression in ovarian cancer and its implication on prognosis. Int J Cancer. 2004; 108(1): 86-90[DOI][PubMed]
  • 31. Agarwal S, Saini S, Parashar D, Verma A, Sinha A, Jagadish N, et al. The novel cancer-testis antigen A-kinase anchor protein 4 (AKAP4) is a potential target for immunotherapy of ovarian serous carcinoma. Oncoimmunology. 2013; 2(5): 24270[DOI][PubMed]
  • 32. Zhang S, Zhou X, Yu H, Yu Y. Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines. BMC Cancer. 2010; 10: 163[DOI][PubMed]
  • 33. Tchabo NE, Mhawech-Fauceglia P, Caballero OL, Villella J, Beck AF, Miliotto AJ. Expression and serum immunoreactivity of developmentally restricted differentiation antigens in epithelial ovarian cancer. Cancer Immunity Archive. 2009; 9(1): 6
  • 34. Zimmermann AK, Imig J, Klar A, Renner C, Korol D, Fink D, et al. Expression of MAGE-C1/CT7 and selected cancer/testis antigens in ovarian borderline tumours and primary and recurrent ovarian carcinomas. Virchows Arch. 2013; 462(5): 565-74[DOI][PubMed]
  • 35. Gjerstorff MF, Johansen LE, Nielsen O, Kock K, Ditzel HJ. Restriction of GAGE protein expression to subpopulations of cancer cells is independent of genotype and may limit the use of GAGE proteins as targets for cancer immunotherapy. Br J Cancer. 2006; 94(12): 1864-73[DOI][PubMed]
  • 36. Odunsi K, Jungbluth AA, Stockert E, Qian F, Gnjatic S, Tammela J, et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res. 2003; 63(18): 6076-83[PubMed]
  • 37. Yakirevich E, Sabo E, Lavie O, Mazareb S, Spagnoli GC, Resnick MB. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms. Clin Cancer Res. 2003; 9(17): 6453-60[PubMed]
  • 38. Esfandiary A, Ghafouri-Fard S. MAGE-A3: an immunogenic target used in clinical practice. Immunotherapy. 2015; 7(6): 683-704[DOI][PubMed]
  • 39. Szajnik M, Derbis M, Lach M, Patalas P, Michalak M, Drzewiecka H, et al. Exosomes in Plasma of Patients with Ovarian Carcinoma: Potential Biomarkers of Tumor Progression and Response to Therapy. Gynecol Obstet (Sunnyvale). 2013; : 3[DOI][PubMed]
  • 40. Daudi S, Eng KH, Mhawech-Fauceglia P, Morrison C, Miliotto A, Beck A, et al. Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer. PLoS One. 2014; 9(8): 104099[DOI][PubMed]
  • 41. Xu Y, Wang C, Zhang Y, Jia L, Huang J. Overexpression of MAGE-A9 Is Predictive of Poor Prognosis in Epithelial Ovarian Cancer. Sci Rep. 2015; 5: 12104[DOI][PubMed]
  • 42. Eng KH, Weir I, Tsuji T, Odunsi K. Immuno-stimultory/regulatory gene expression patterns in advanced ovarian cancer. Genes Cancer. 2015; 6(9-10): 399-407[DOI][PubMed]
  • 43. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005; 102(51): 18538-43[DOI][PubMed]
  • 44. Milne K, Barnes RO, Girardin A, Mawer MA, Nesslinger NJ, Ng A, et al. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer. PLoS One. 2008; 3(10): 3409[DOI][PubMed]
  • 45. Tammela J, Uenaka A, Ono T, Noguchi Y, Jungbluth AA, Mhawech-Fauceglia P, et al. OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer. Int J Oncol. 2006; 29(4): 903-10[PubMed]
  • 46. Fan R, Huang W, Luo B, Zhang QM, Xiao SW, Xie XX. Cancer testis antigen OY-TES-1: analysis of protein expression in ovarian cancer with tissue microarrays. Eur J Gynaecol Oncol. 2015; 36(3): 298-303[PubMed]
  • 47. Khan G, Brooks SE, Mills KI, Guinn BA. Infrequent Expression of the Cancer-Testis Antigen, PASD1, in Ovarian Cancer. Biomark Cancer. 2015; 7: 31-8[DOI][PubMed]
  • 48. Ghafouri-Fard S, Rezazadeh F, Zare-Abdollahi D, Omrani MD, Movafagh A. Are so-called cancer-testis genes expressed only in testis? Asian Pac J Cancer Prev. 2014; 15(18): 7703-5[PubMed]
  • 49. Lim SL, Ricciardelli C, Oehler MK, Tan IM, Russell D, Grutzner F. Overexpression of piRNA pathway genes in epithelial ovarian cancer. PLoS One. 2014; 9(6): 99687[DOI][PubMed]
  • 50. Chen C, Liu J, Xu G. Overexpression of PIWI proteins in human stage III epithelial ovarian cancer with lymph node metastasis. Cancer Biomark. 2013; 13(5): 315-21[DOI][PubMed]
  • 51. Tammela J, Jungbluth AA, Qian F, Santiago D, Scanlan MJ, Keitz B. SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer. Cancer Immunity Archive. 2004; 4(1): 10
  • 52. Yamada R, Takahashi A, Torigoe T, Morita R, Tamura Y, Tsukahara T, et al. Preferential expression of cancer/testis genes in cancer stem-like cells: proposal of a novel sub-category, cancer/testis/stem gene. Tissue Antigens. 2013; 81(6): 428-34[DOI][PubMed]
  • 53. Koslowski M, Tureci O, Bell C, Krause P, Lehr HA, Brunner J, et al. Multiple splice variants of lactate dehydrogenase C selectively expressed in human cancer. Cancer Res. 2002; 62(22): 6750-5[PubMed]
  • 54. Neesse A, Gangeswaran R, Luettges J, Feakins R, Weeks ME, Lemoine NR, et al. Sperm-associated antigen 1 is expressed early in pancreatic tumorigenesis and promotes motility of cancer cells. Oncogene. 2007; 26(11): 1533-45[DOI][PubMed]
  • 55. Almanzar G, Olkhanud PB, Bodogai M, Dell'agnola C, Baatar D, Hewitt SM, et al. Sperm-derived SPANX-B is a clinically relevant tumor antigen that is expressed in human tumors and readily recognized by human CD4+ and CD8+ T cells. Clin Cancer Res. 2009; 15(6): 1954-63[DOI][PubMed]
  • 56. Kouprina N, Noskov VN, Pavlicek A, Collins NK, Schoppee Bortz PD, Ottolenghi C, et al. Evolutionary diversification of SPANX-N sperm protein gene structure and expression. PLoS One. 2007; 2(4): 359[DOI][PubMed]
  • 57. Tureci O, Chen YT, Sahin U, Gure AO, Zwick C, Villena C, et al. Expression of SSX genes in human tumors. Int J Cancer. 1998; 77(1): 19-23[PubMed]
  • 58. Hasegawa K, Koizumi F, Noguchi Y, Hongo A, Mizutani Y, Kodama J, et al. SSX expression in gynecological cancers and antibody response in patients. Cancer Immun. 2004; 4: 16[PubMed]
  • 59. Valmori D, Qian F, Ayyoub M, Renner C, Merlo A, Gnjatic S, et al. Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells. Clin Cancer Res. 2006; 12(2): 398-404[DOI][PubMed]
  • 60. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A. 1995; 92(25): 11810-3[PubMed]
  • 61. Adair SJ, Carr TM, Fink MJ, Slingluff CJ, Hogan KT. The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes. J Immunother. 2008; 31(1): 7-17[DOI][PubMed]
  • 62. Modarressi MH, Cameron J, Taylor KE, Wolfe J. Identification and characterisation of a novel gene, TSGA10, expressed in testis. Gene. 2001; 262(1-2): 249-55[PubMed]
  • 63. Mobasheri MB, Jahanzad I, Mohagheghi MA, Aarabi M, Farzan S, Modarressi MH. Expression of two testis-specific genes, TSGA10 and SYCP3, in different cancers regarding to their pathological features. Cancer Detect Prev. 2007; 31(4): 296-302[DOI][PubMed]
  • 64. Mobasheri MB, Modarressi MH, Shabani M, Asgarian H, Sharifian RA, Vossough P. Expression of the testis-specific gene, TSGA10, in Iranian patients with acute lymphoblastic leukemia (ALL). Leukemia Res. 2006; 30(7): 883-9
  • 65. Tanaka R, Ono T, Sato S, Nakada T, Koizumi F, Hasegawa K, et al. Over-expression of the testis-specific gene TSGA10 in cancers and its immunogenicity. Microbiol Immunol. 2004; 48(4): 339-45[PubMed]
  • 66. Hoei-Hansen CE, Kraggerud SM, Abeler VM, Kaern J, Rajpert-De Meyts E, Lothe RA. Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers. Mol Cancer. 2007; 6: 12[DOI][PubMed]
  • 67. Mills GB, Schmandt R, McGill M, Amendola A, Hill M, Jacobs K, et al. Expression of TTK, a novel human protein kinase, is associated with cell proliferation. J Biol Chem. 1992; 267(22): 16000-6[PubMed]
  • 68. Mizukami Y, Kono K, Daigo Y, Takano A, Tsunoda T, Kawaguchi Y, et al. Detection of novel cancer-testis antigen-specific T-cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma. Cancer Sci. 2008; 99(7): 1448-54[DOI][PubMed]
  • 69. Egland KA, Kumar V, Duray P, Pastan I. Characterization of overlapping XAGE-1 transcripts encoding a cancer testis antigen expressed in lung, breast, and other types of cancers. Mol Cancer Ther. 2002; 1(7): 441-50[PubMed]
  • 70. Sato S, Noguchi Y, Ohara N, Uenaka A, Shimono M, Nakagawa K, et al. Identification of XAGE-1 isoforms: predominant expression of XAGE-1b in testis and tumors. Cancer Immun. 2007; 7: 5[PubMed]
  • 71. Philip R, Murthy S, Krakover J, Sinnathamby G, Zerfass J, Keller L, et al. Shared immunoproteome for ovarian cancer diagnostics and immunotherapy: potential theranostic approach to cancer. J Proteome Res. 2007; 6(7): 2509-17[DOI][PubMed]
  • 72. Esfandiary A, Ghafouri-Fard S. New York esophageal squamous cell carcinoma-1 and cancer immunotherapy. Immunotherapy. 2015; 7(4): 411-39[DOI][PubMed]
  • 73. Qian F, Gnjatic S, Jager E, Santiago D, Jungbluth A, Grande C, et al. Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer. Cancer Immun. 2004; 4: 12[PubMed]
  • 74. Odunsi K, Matsuzaki J, James SR, Mhawech-Fauceglia P, Tsuji T, Miller A, et al. Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. Cancer Immunol Res. 2014; 2(1): 37-49[DOI][PubMed]
  • 75. Garg M, Chaurasiya D, Rana R, Jagadish N, Kanojia D, Dudha N, et al. Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer. Clin Cancer Res. 2007; 13(5): 1421-8[DOI][PubMed]
  • 76. Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller A, et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A. 2012; 109(15): 5797-802[DOI][PubMed]
  • 77. Batchu RB, Gruzdyn OV, Moreno-Bost AM, Szmania S, Jayandharan G, Srivastava A, et al. Efficient lysis of epithelial ovarian cancer cells by MAGE-A3-induced cytotoxic T lymphocytes using rAAV-6 capsid mutant vector. Vaccine. 2014; 32(8): 938-43[DOI][PubMed]
  • 78. Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW, et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A. 2007; 104(31): 12837-42[DOI][PubMed]
  • 79. Vaccine therapy in treating patients with metastatic cancer.
  • 80. Vaccine therapy in treating patients with ovarian epithelial, primary peritoneal, or fallopian tube cancer.
  • 81. Safety and immunogenicity of chp-her2 and chp-ny-eso-1 protein with ok-432 in antigen-expressing cancers.
  • 82. Nishikawa H, Qian F, Tsuji T, Ritter G, Old LJ, Gnjatic S, et al. Influence of CD4+CD25+ regulatory T cells on low/high-avidity CD4+ T cells following peptide vaccination. J Immunol. 2006; 176(10): 6340-6[PubMed]
  • 83. A phase i study of ny-eso-1 overlapping peptides (olp4) immunoadjuvants montanide and poly-iclc vaccination of epithelial ovarian cancer (eoc), fallopian tube, or primary peritoneal cancer patients in second or third remission.
  • 84. Tsuji T, Sabbatini P, Jungbluth AA, Ritter E, Pan L, Ritter G, et al. Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial. Cancer Immunol Res. 2013; 1(5): 340-50[DOI][PubMed]
  • 85. Leffers N, Daemen T, Helfrich W, Boezen HM, Cohlen BJ, Melief CJ, et al. Antigen-specific active immunotherapy for ovarian cancer. Cochrane Database Syst Rev. 2014; (9)[DOI][PubMed]
  • 86. Chianese-Bullock KA, Irvin WJ, Petroni GR, Murphy C, Smolkin M, Olson WC, et al. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. J Immunother. 2008; 31(4): 420-30[DOI][PubMed]
  • 87. Vaccine therapy in treating patients with stage ii, stage iii, or stage iv ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cavity cancer.
  • 88. Decitabine, vaccine therapy, and pegylated liposomal doxorubicin hydrochloride in treating patients with recurrent ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer.
  • 89. Vaccine therapy with or without sirolimus in treating patients with ny-eso-1 expressing solid tumors.
  • 90. Sirolimus and vaccine therapy in treating patients with stage ii-iv ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer.
  • 91. Matsuzaki J, Tsuji T, Luescher I, Old LJ, Shrikant P, Gnjatic S, et al. Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells. Cancer Immunol Res. 2014; 2(4): 341-50[DOI][PubMed]
  • 92. A phase 1 trial of ny-eso-1 with gla-se in patients with unresectable or metastatic cancer.
  • 93. Ny-eso-1-specific t-cells in treating patients with advanced ny-eso-1-expressing sarcomas receiving palliative radiation therapy.
  • 94. Investigator initiated phase 1 study of tbi-1301.
  • 95. T cell receptor-transduced t cells targeting ny-eso-1 for treatment of patients with ny-eso-1- expressing malignancies.
  • 96. Clinical trial of a therapeutic vaccine with ny-eso-1 in combination with the adjuvant monophosphoryl lipid a (mpla).
  • 97. Ct antigen tcr-redirected t cells for ovarian cancer.
  • 98. Vaccine therapy and ido1 inhibitor incb024360 in treating patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in remission.
  • 99. Dec-205/ny-eso-1 fusion protein cdx-1401, poly iclc, and ido1 inhibitor incb024360 in treating patients with ovarian, fallopian tube, or primary peritoneal cancer in remission.
  • 100. Vaccine therapy in treating patients with stage ii, stage iii, or stage iv ovarian epithelial, fallopian tube, or peritoneal cancer.
  • 101. Vaccine therapy, paclitaxel, and carboplatin in treating patients who are undergoing surgery for stage iii or stage iv ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
  • 102. Hofmann M, Ruschenburg I. mRNA detection of tumor-rejection genes BAGE, GAGE, and MAGE in peritoneal fluid from patients with ovarian carcinoma as a potential diagnostic tool. Cancer. 2002; 96(3): 187-93[DOI][PubMed]
  • 103. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A. 1997; 94(5): 1914-8[PubMed]
  • 104. Jager E, Karbach J, Gnjatic S, Neumann A, Bender A, Valmori D, et al. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci U S A. 2006; 103(39): 14453-8[DOI][PubMed]
  • 105. Tchabo NE, Mhawech-Fauceglia P, Caballero OL, Villella J, Beck AF, Miliotto AJ, et al. Expression and serum immunoreactivity of developmentally restricted differentiation antigens in epithelial ovarian cancer. Cancer Immun. 2009; 9: 6[PubMed]
  • 106. Gillespie AM, Rodgers S, Wilson AP, Tidy J, Rees RC, Coleman RE, et al. MAGE, BAGE and GAGE: tumour antigen expression in benign and malignant ovarian tissue. Br J Cancer. 1998; 78(6): 816-21[PubMed]
  • 107. Yamada A, Kataoka A, Shichijo S, Kamura T, Imai Y, Nishida T, et al. Expression of MAGE-1, MAGE-2, MAGE-3/-6 and MAGE-4a/-4b genes in ovarian tumors. Int J Cancer. 1995; 64(6): 388-93[PubMed]
  • 108. Lee JH, Schutte D, Wulf G, Fuzesi L, Radzun HJ, Schweyer S, et al. Stem-cell protein Piwil2 is widely expressed in tumors and inhibits apoptosis through activation of Stat3/Bcl-XL pathway. Hum Mol Genet. 2006; 15(2): 201-11[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments